RF GP Ablation Added to PEF PVI for Paroxysmal AF (REGATTA-AF)
RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation (REGATTA-AF Study)
This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.
The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.
The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.
The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Prague
-
Prague, Prague, Tchéquie, 14200
- Institute for Clinical and Experimental Medicine
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:
- Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
- Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
-
Patients who are ≥30 and ≤65 years of age on the day of enrolment.
-
Patients who are willing and capable of:
- Providing informed consent to undergo study procedures AND
- Participating in all examinations, follow-up visits, and tests associated with this clinical study.
-
Effective contraception for women of childbearing potential.
-
Effective oral anticoagulation for >3 weeks before the planned ablation procedure.
Exclusion Criteria:
- Persistent, long-standing persistent, or permanent AF.
- AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
- Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
- Left ventricular ejection fraction <40%.
- Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
- Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
- Any prior atrial surgery.
- Intra-atrial septal patch or interatrial shunt.
- General contraindications of catheter ablation
- LA appendage closure, device, or occlusion, past or anticipated.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: RF GP + PEF PVI
Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field |
isolation of pulmonary veins and roof line ablation using pulsed electric energy ablation of GP using radiofrequency energy |
|
Comparateur actif: PEF PVI
Pulmonary vein isolation and roof line ablation using pulsed electric field energy |
isolation of pulmonary veins and roof line ablation using pulsed electric energy |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Freedom from recurrent AF/AT >30 s during the first 12 months
Délai: From the ablation procedure through the 12-month follow-up.
|
The primary outcome of the study is freedom from recurrent AF/AT >30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs. |
From the ablation procedure through the 12-month follow-up.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of life
Délai: Baseline and at the 12-month visit.
|
This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life). |
Baseline and at the 12-month visit.
|
|
Periprocedural complications, MACE
Délai: From the ablation procedure through the 12-month follow-up.
|
periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up |
From the ablation procedure through the 12-month follow-up.
|
|
Acute vagal denervation assessed by ECVS
Délai: Periprocedural
|
ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded. |
Periprocedural
|
|
Long-term cardiac vagal denervation
Délai: Baseline and at the 12-month visit.
|
Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection. |
Baseline and at the 12-month visit.
|
|
Vagal atrial induction test (VAFIT)
Délai: Periprocedural
|
This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS. |
Periprocedural
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IClinicalEM
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .